135 Stock Chart & Stats
€4.50
€0.00(0.00%)
At close: 4:00 PM EDT
€4.50
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.82 - €7.86
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€45.07M
Enterprise Value-€10.56
Total Cash (Recent Filing)€54.08M
Total Debt (Recent Filing)€1.95M
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Nov 11, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.83
Shares Outstanding9,930,329
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€15.16Price Target Upside236.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.84
Revenue Forecast (FY)€1.02M
Bulls Say, Bears Say
Bulls Say
Approved Lead ProductRegulatory approval of ibrexafungerp (BREXAFEMME) establishes a commercial foothold and de-risks part of development pipeline. An approved asset provides durable revenue potential via product sales and partner royalties while enabling further label expansion and lifecycle planning.
Partner-based Commercial ModelA partnership-driven commercialization approach reduces fixed selling costs and leverages partners' regional infrastructure. This model shifts revenue to scalable royalties and milestone payments, improving capital efficiency and allowing the company to focus on R&D and regulatory execution over long-term sales buildout.
Conservative Balance Sheet LeverageLow leverage provides financial flexibility to fund clinical programs, pursue partnerships, or bridge cash needs without immediate distress. A conservative capital structure supports longer-term R&D timelines and reduces default risk, important for biotech firms with lumpy cash flows.
Bears Say
Negative Cash FlowSustained negative operating and free cash flow means the company requires external financing or partner funding to sustain operations and trials. Persistent cash burn increases dilution risk and can constrain strategic options, affecting long-term program continuity and investor returns.
Volatile, Lumpy RevenueMeaningful year-to-year swings—from high growth to sizable losses—indicate revenue reliance on one-off events, milestones, or limited product rollouts. This volatility undermines predictability for funding, planning, and sustaining R&D, leaving the business exposed if milestone timing shifts or partner sales underperform.
Equity Dilution / Share Overhang RiskAuthorization to increase shares, expanded equity compensation capacity, and a large resale registration create potential future share supply and dilution. Such structural overhang can pressure long-term per-share economics and complicate equity financing timing during continued cash burn or program needs.
SCYNEXIS News
135 FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest stock price was €3.82 and its highest was €7.86 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is €45.07M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is Nov 11, 2026 which is in 92 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on Aug 10, 2026. The company reported €0.546 earnings per share for the quarter, beating the consensus estimate of -€0.439 by €0.985.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -0.44.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 9,930,329 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of €0.546 in its last earnings report, beating expectations of -€0.439. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of SCYNEXIS?
Currently, no hedge funds are holding shares in DE:135
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SCYNEXIS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€15.16 (236.82% Upside)
€15.16 (236.82% Upside)
Blogger Sentiment
Bullish
DE:135 Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.30%
Trailing 12-Months
Company Description
SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
135 Stock 12 Month Forecast
Average Price Target
€15.16
▲(236.82% Upside)
Technical Analysis
Rockwell Med
―
TherapeuticsMD
―
Aytu BioScience
―
Cumberland Pharmaceuticals
―
IM Cannabis Corp
―